Veeva Systems INC: insider trades · United States · SEC (Form 4)

About Veeva Systems INC

Veeva Systems Inc. is a U.S.-based enterprise software company focused on cloud software, data, artificial intelligence, and consulting for the global life sciences industry. The company is listed in the United States on the NYSE under the ticker VEEV. It was founded in 2007, and its headquarters are in Pleasanton, California, United States. Veeva’s business model is built around a vertical industry platform designed for the operational, regulatory, and commercial needs of pharmaceuticals, biotechnology companies, and other highly regulated life sciences organizations. Its core product stack spans Vault Platform, Vault CRM, Veeva Quality Cloud, Veeva Clinical, Veeva Regulatory, Veeva Safety, Veeva Medical, Veeva Commercial Cloud, and Veeva Data Cloud. More recently, the company has been pushing Veeva AI, a set of domain-specific AI capabilities and agents intended to work deeply inside Veeva applications. This is strategically important because Veeva is not selling generic software; it is offering workflow-heavy, compliance-aware applications tailored to the life sciences value chain. From a competitive standpoint, Veeva holds a leading position in vertical cloud software for life sciences. Its moat is driven by industry specialization, long customer relationships, recurring subscription revenues, and the breadth of its platform, which extends from R&D and clinical operations to quality, regulatory, medical affairs, and commercial execution. In recent corporate communications, Veeva has highlighted the expansion of Vault CRM, growing adoption of Veeva Basics by emerging biotechs, and early momentum around AI-enabled products. That combination reinforces the company’s reputation as a mission-critical vendor rather than a discretionary IT provider. Geographically, Veeva serves customers globally, with a commercial footprint and support capabilities across multiple regions, while maintaining its corporate base in California. Recent notable developments include the rollout of Veeva AI Agents across applications, new biotech-focused product introductions, collaboration announcements related to clinical-trial innovation, and strong quarterly results in 2025 and early 2026, supported by solid subscription revenue growth. For investors, Veeva stands out as a high-quality growth name in the Health & Pharma sector, with exposure to a structurally resilient end market and a differentiated software franchise built on deep domain expertise.